Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate - Philikos

Next Previous
Drug Profile

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate - Philikos

Alternative Names: HENO 3; MabCD3-dgA/CD7-dgA; T-Guard

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radboud-University-Nijmegen-Medical-Centre
  • Developer Philikos; Radboud University Nijmegen Medical Centre; Xenikos
  • Class Drug conjugates; Immunotoxins; Lectins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Graft-versus-host disease

Highest Development Phases

  • Phase I/II Diffuse scleroderma
  • Preclinical Autoimmune disorders
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 20 May 2025 Phase-I/II clinical trials in Diffuse scleroderma (Treatment-experienced) (IV) prior to May 2025 (EudraCT2024-517283-28-00)
  • 06 Dec 2024 Discontinued - Phase-III for Graft-versus-host disease (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in USA (IV) (Xenikos pipeline, December 2024)
  • 06 Dec 2024 Discontinued - Phase-III for Graft-versus-host disease (In the elderly, In adults) in United Kingdom, Croatia, Italy, Netherlands, Germany, Germany, Spain, France, France, Belgium (IV) (Xenikos pipeline, December 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top